These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 32483674)
1. Alendronate use and bone mineral density gains in women with moderate-severe (stages 3B-5) chronic kidney disease: an open cohort multivariable and propensity score analysis from Funen, Denmark. Ali MS; Ernst M; Robinson DE; Caskey F; Arden NK; Ben-Shlomo Y; Nybo M; Rubin KH; Judge A; Cooper C; Javaid MK; Hermann AP; Prieto-Alhambra D Arch Osteoporos; 2020 Jun; 15(1):81. PubMed ID: 32483674 [TBL] [Abstract][Full Text] [Related]
2. Bisphosphonates to reduce bone fractures in stage 3B+ chronic kidney disease: a propensity score-matched cohort study. Robinson DE; Ali MS; Strauss VY; Elhussein L; Abrahamsen B; Arden NK; Ben-Shlomo Y; Caskey F; Cooper C; Dedman D; Delmestri A; Judge A; Javaid MK; Prieto-Alhambra D Health Technol Assess; 2021 Mar; 25(17):1-106. PubMed ID: 33739919 [TBL] [Abstract][Full Text] [Related]
3. The association between renal function and BMD response to bisphosphonate treatment: Real-world cohort study using linked national registers. Abrahamsen B; Ernst MT; Smith CD; Nybo M; Rubin KH; Prieto-Alhambra D; Hermann AP Bone; 2020 Aug; 137():115371. PubMed ID: 32334104 [TBL] [Abstract][Full Text] [Related]
4. Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis. Planas J; Trilla E; Raventós C; Cecchini L; Orsola A; Salvador C; Placer J; Encabo G; Morote J BJU Int; 2009 Dec; 104(11):1637-40. PubMed ID: 19549260 [TBL] [Abstract][Full Text] [Related]
5. Effects of alendronate and calcitonin on bone mineral density in postmenopausal osteoporotic women. An observational study. Hejdova M; Palicka V; Kucera Z; Vlcek J Pharm World Sci; 2005 Jun; 27(3):149-53. PubMed ID: 16096879 [TBL] [Abstract][Full Text] [Related]
6. Impact of hepatitis C virus infection on bone mineral density in renal transplant recipients. Huang WH; Yu MC; Huang JY; Lai PC PLoS One; 2013; 8(5):e63263. PubMed ID: 23675468 [TBL] [Abstract][Full Text] [Related]
7. Bone Mineral Density After Transitioning From Denosumab to Alendronate. Kendler D; Chines A; Clark P; Ebeling PR; McClung M; Rhee Y; Huang S; Stad RK J Clin Endocrinol Metab; 2020 Mar; 105(3):e255-64. PubMed ID: 31665314 [TBL] [Abstract][Full Text] [Related]
8. Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday. Xu LH; Adams-Huet B; Poindexter JR; Maalouf NM Osteoporos Int; 2016 May; 27(5):1701-8. PubMed ID: 26642963 [TBL] [Abstract][Full Text] [Related]
9. Effectiveness of alendronate and etidronate in the treatment of osteoporosis in men: a prospective observational study. Olszynski WP; Davison KS; Ioannidis G; Brown JP; Hanley DA; Josse RG; Murray TM; Papaioannou A; Sebaldt RJ; Tenenhouse AM; Petrie A; Goldsmith CH; Adachi JD Osteoporos Int; 2006 Feb; 17(2):217-24. PubMed ID: 15997420 [TBL] [Abstract][Full Text] [Related]
10. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study. Roux C; Hofbauer LC; Ho PR; Wark JD; Zillikens MC; Fahrleitner-Pammer A; Hawkins F; Micaelo M; Minisola S; Papaioannou N; Stone M; Ferreira I; Siddhanti S; Wagman RB; Brown JP Bone; 2014 Jan; 58():48-54. PubMed ID: 24141036 [TBL] [Abstract][Full Text] [Related]
11. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis. Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968 [TBL] [Abstract][Full Text] [Related]
12. Changes in bone mineral density after kidney transplantation: 2-year assessment of a French cohort. Segaud N; Legroux I; Hazzan M; Noel C; Cortet B Osteoporos Int; 2018 May; 29(5):1165-1175. PubMed ID: 29500526 [TBL] [Abstract][Full Text] [Related]
13. Periarticular and generalised bone loss in patients with early rheumatoid arthritis: influence of alendronate and intra-articular glucocorticoid treatment. Post hoc analyses from the CIMESTRA trial. Jensen TW; Hansen MS; Hørslev-Petersen K; Hyldstrup L; Abrahamsen B; Langdahl B; Zerahn B; Pødenphant J; Stengaard-Petersen K; Junker P; Østergaard M; Lottenburger T; Ellingsen T; Andersen LS; Hansen I; Skjødt H; Pedersen JK; Lauridsen UB; Svendsen AJ; Tarp U; Lindegaard H; Jurik AG; Vestergaard A; Hetland ML; Ann Rheum Dis; 2014 Jun; 73(6):1123-9. PubMed ID: 23661492 [TBL] [Abstract][Full Text] [Related]
14. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. McComsey GA; Kendall MA; Tebas P; Swindells S; Hogg E; Alston-Smith B; Suckow C; Gopalakrishnan G; Benson C; Wohl DA AIDS; 2007 Nov; 21(18):2473-82. PubMed ID: 18025884 [TBL] [Abstract][Full Text] [Related]
15. Effect of bisphosphonate treatment on bone mineral density in patients with thalassaemia major. Skordis N; Ioannou YS; Kyriakou A; Savva SC; Efstathiou E; Savvides I; Christou S Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():144-8. PubMed ID: 19337169 [TBL] [Abstract][Full Text] [Related]
16. Denosumab Safety and Efficacy Among Participants in the FREEDOM Extension Study With Mild to Moderate Chronic Kidney Disease. Broadwell A; Chines A; Ebeling PR; Franek E; Huang S; Smith S; Kendler D; Messina O; Miller PD J Clin Endocrinol Metab; 2021 Jan; 106(2):397-409. PubMed ID: 33211870 [TBL] [Abstract][Full Text] [Related]
17. Denosumab versus alendronate in long-term glucocorticoid users: A 12-month randomized controlled trial. Mok CC; Ho LY; Leung SMT; Cheung HN; Chen SPL; Ma KM Bone; 2021 May; 146():115902. PubMed ID: 33631355 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study. Emkey R; Delmas PD; Bolognese M; Borges JL; Cosman F; Ragi-Eis S; Recknor C; Zerbini CA; Neate C; Sedarati F; Epstein S Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148 [TBL] [Abstract][Full Text] [Related]
19. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial. Barone A; Giusti A; Pioli G; Girasole G; Razzano M; Pizzonia M; Palummeri E; Bianchi G J Am Geriatr Soc; 2007 May; 55(5):752-7. PubMed ID: 17493196 [TBL] [Abstract][Full Text] [Related]
20. Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis. Ringe JD; Möller G Rheumatol Int; 2009 Dec; 30(2):213-21. PubMed ID: 19430791 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]